Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

A subcutaneous insulin-driven treatment protocol for diabetic ketoacidosis (DKA), instead of continuous intravenous insulin, can reduce intensive care unit (ICU) admission and hospital readmission in ...

Treatment with SC vs IV tocilizumab led to higher long-term remission rates in GCA-associated aortitis, though imaging and glucocorticoid-sparing outcomes were similar.

Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...

In brief, 167 participants were randomly assigned to the subcutaneous-administration group and 191 participants to the intradermal-administration group. The demographic characteristics of the ...

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...